| Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics. | |
| | |
MedLine Citation:
|
PMID: 20198346 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Inactivation of tumor suppressor genes is a major contributing alteration in the initiation or progression of cancer. The human tumor suppressor gene DLC1 (deleted in liver cancer 1) is frequently downregulated or silenced in multiple cancers, predominantly by epigenetic mechanisms. With the current considerable interest and progress in epigenetic therapy, a number of promising antineoplastic agents, particularly histone deacetylase (HDAC) inhibitors, have been developed and used successfully in clinical trials. Both DLC1 and HDAC inhibitors exert antineoplastic functions, and their combined action could be exploited for a more effective cancer therapy. To evaluate the potential benefits of this approach, we examined the antineoplastic effects of adenoviral (Ad)-DLC1-mediated transduction and exposure to suberoylanilide hydroxamic acid (SAHA), a powerful HDAC inhibitor, in two human cancer cell lines that lack intrinsic DLC1 expression, 22Rv1 prostate cancer cells and 7703K human hepatocellular carcinoma cells. Consistent with the oncosuppressive function of DLC1 in several cancers, including prostate and liver cancer, transduction of 22Rv1 and 7703K cells with an Ad-DLC1 expression vector resulted in alterations of cell morphology, induction of apoptosis, and inhibition of cell proliferation, migration, and anchorage-independent growth. A low concentration of SAHA (5 microM) efficiently restored the expression of DLC1 in 22Rv1 cells that lack DLC1 expression due to histone deacetylation but had a minimal effect in 7703K cells in which silencing of the DLC1 gene is due mainly to promoter hypermethylation. Regardless of the epigenetic mechanism of DLC1 inactivation, SAHA treatment of DLC1-transduced cells had a synergistic inhibitory effect on tumor cell proliferation and tumorigenesis in both cell lines. In 22Rv1 cells, this combination regimen nearly abolished the formation of colonies in semisolid media as a measure of tumorigenicity in vitro. Current in vitro results validate this protocol as a potentially new therapeutic option in certain cancers. |
| | |
Authors:
|
Xiaoling Zhou; Xu-Yu Yang; Nicholas C Popescu |
Related Documents
:
|
19491256 - Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. 10458476 - Pathophysiologic significance of host reactions in human cancer tissue: desmoplasia and... 10810336 - Inhibition of mda-mb-231 human breast tumor xenografts and her2 expression by anti-tumo... 12413846 - Sulfamoyloxy-substituted 2-phenylindoles: antiestrogen-based inhibitors of the steroid ... 1621696 - Bladder cancer and occupation in shanghai, 1980-1984. 15757426 - Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Intramural |
Journal Detail:
|
Title: International journal of oncology Volume: 36 ISSN: 1791-2423 ISO Abbreviation: Int. J. Oncol. Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-03-03 Completed Date: 2010-06-04 Revised Date: 2011-10-03 |
Medline Journal Info:
|
Nlm Unique ID: 9306042 Medline TA: Int J Oncol Country: Greece |
Other Details:
|
Languages: eng Pagination: 999-1005 Citation Subset: IM |
Affiliation:
|
Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenoviridae
/
genetics Apoptosis / drug effects Caspase 3 / metabolism Cell Line, Tumor Cell Movement / drug effects Cell Proliferation / drug effects Cell Shape / drug effects Cell Survival / drug effects Enzyme Activation GTPase-Activating Proteins Gene Therapy* Genetic Vectors Histone Deacetylase Inhibitors / pharmacology* Humans Hydroxamic Acids / pharmacology* Liver Neoplasms / genetics, metabolism, pathology, therapy* Male Promoter Regions, Genetic / drug effects Prostatic Neoplasms / genetics, metabolism, pathology, therapy* RNA, Messenger / metabolism Time Factors Transduction, Genetic Tumor Suppressor Proteins / biosynthesis, genetics* |
| Chemical | |
Reg. No./Substance:
|
0/DLC1 protein, human; 0/GTPase-Activating Proteins; 0/Histone Deacetylase Inhibitors; 0/Hydroxamic Acids; 0/RNA, Messenger; 0/Tumor Suppressor Proteins; 149647-78-9/vorinostat; EC 3.4.22.-/CASP3 protein, human; EC 3.4.22.-/Caspase 3 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The cell cycle effects of docosahexaenoic acid on human metastatic hepatocellular carcinoma prolifer...
Next Document: Differential effects of resveratrol and novel resveratrol derivative, HS-1793, on endoplasmic reticu...